<DOC>
	<DOCNO>NCT02161796</DOCNO>
	<brief_summary>This study evaluate concentration FG-4592 blood certain period intake different dos , ass effect , safety tolerability study drug healthy young elderly male female subject . On Day 1 4 period subject receive different single dos FG-4592 placebo , depend treatment sequence randomize . For period subject remain clinic 6 day ( Days -2 4 ) . They discharge assessment complete Day 4 period , return End Study visit ( ESV ) 5 9 day last assessment Period 4 .</brief_summary>
	<brief_title>A Study Evaluate Dose-proportionality Effects FG-4592 Healthy Young Elderly Male Female Subjects</brief_title>
	<detailed_description>In study eligible subject reside clinic 4 period 6 day ( Day -2 Day 4 ) . Screening take place Day -23 Day -3 . Subjects admit clinic Day -2 Period 1 . Within cohort ( young elderly subject ) , subject randomize one 24 treatment sequence 4 treatment option ( 3 different dos FG-4592 placebo ) 4 period . On Day 1 period , subject receive single oral dose FG-4592 placebo follow 72-hour evaluation period . Subjects discharge Day 4 , medical reason prolong stay . Each period separate wash-out period least 10 day dose Day 1 previous period dose Day 1 follow period . The subject return end-of-study visit ( ESV ) 5-9 day last assessment Period 4 ( early withdrawal ) . Plasma urine sample collect pharmacokinetic ( PK ) pharmacodynamic ( PD ) assessment . Safety assessment perform throughout study .</detailed_description>
	<criteria>YOUNG : Subject healthy young male healthy female subject age 18 45 year age inclusive ELDERLY : Subject healthy elderly male female subject age 65 Male subject female spouse/partners childbearing potential must use highly effective contraception consist 2 form birth control Male subject must donate sperm start screen throughout study period 90 day final study drug administration Female subject must either nonchildbearing potential , childbearing potential , must negative pregnancy test screen Day 2 must use 2 form birth control Female subject must breastfeed screen study period 28 day final study drug administration Female subject must donate ovum start screen throughout study period 28 day final study drug administration Female subject pregnant within 6 month screen breastfeed within 3 month screen Subject use grapefruit , grapefruit juice ( 3 x 200 mL ) orange marmalade ( 3 time ) week prior admission clinic ESV The subject vulnerable subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>FG-4592</keyword>
	<keyword>Age/gender comparison</keyword>
</DOC>